Sandoz and Polpharma Biologics have become the first companies to get FDA approval for a biosimilar of Biogen's blockbuster multiple sclerosis therapy Tysabri, after overcoming a bid by Biogen to ...

Balancing risk and benefit Biogen’s recombinant humanized monoclonal antibody, natalizumab (TYSABRI®), mediates lymphocyte and monocyte cell adhesion and transendothelial migration via the ...

Biogen has finalised a $900 million payment ... and meals to induce them to prescribe the MS drugs Avonex (interferon-beta-1a), Tysabri (natalizumab), and Tecfidera (dimethyl fumarate) between ...

Sales of Biogen’s key multiple sclerosis (“MS”) drugs like Tecfidera and Tysabri and spinal muscular atrophy (SMA) treatment, Spinraza are declining due to competitive pressure. Biogen has ...

Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers ...

BTIG analyst Thomas Shrader has maintained their neutral stance on BIIB stock, giving a Hold rating on January 23.Invest with Confidence: ...

Biogen's stock underperformed in 2024 due to ... Tecfidera faces competition from generic versions, while Tysabri competes with other high-efficacy MS therapies and biosimilars.

Biogen, Inc. is a biopharmaceutical company ... Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM ...

The Japanese and American based pharma companies announced a win for their Alzheimer’s treatment, which has faced some negative backlash over the last year.